This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
by Zacks Equity Research
Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.
Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
by Zacks Equity Research
How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?
Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
by Zacks Equity Research
Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.
The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway
Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit
by Zacks Equity Research
Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
by Zacks Equity Research
Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
by Zacks Equity Research
We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.
The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal
Biogen (BIIB) Presents Positive Phase III Data on Spinraza
by Zacks Equity Research
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
by Arpita Dutt
Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
by Zacks Equity Research
Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
AbbVie's Humira and Imbruvica Drive Performance in 2016
by Zacks Equity Research
AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.
Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
by Arpita Dutt
Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.
Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
by Zacks Equity Research
Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Biogen (BIIB) Board Okays Hemophilia Business Spin-off
by Zacks Equity Research
Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.
Biogen Names Commercial Officer as New CEO, Shares Fall
by Zacks Equity Research
Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.
The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & ChemicalThe Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
Top Research Reports for Barclays, Netflix and Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Barclays (BCS), Netflix (NFLX) and NIKE (NKE).
Biogen Presents Positive Early Data from Alzheimer's Study
by Zacks Equity Research
Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
Lilly/AstraZeneca Expand Alzheimer Disease Collaboration
by Zacks Equity Research
Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814
Stock Market News for December 08, 2016
by Zacks Equity Research
The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.